Cerebrospinal fluid as liquid biopsy for characterising & policing of medulloblastoma

27 Oct 2020
Cerebrospinal fluid as liquid biopsy for characterising & policing of medulloblastoma

Cerebrospinal fluid as liquid biopsy for the precise characterisation and policing of medulloblastoma

Results from a proof-of-concept study led by Joan Seoane show the promise of cerebrospinal fluid as liquid biopsy for the more precise characterisation and real time tracking of medulloblastoma.

Circulating tumour DNA from cerebrospinal fluid reveals genomic alterations during disease evolution -even prior to surgery- to more precisely guide treatment decision making.

Cerebrospinal fluid as liquid biopsy against medulloblastoma translates in less invasive sampling, better identification and characterisation of disease relapse.

Building on previous research 1 - 3 led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA), allows for the more precise characterisation, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumour in childhood.

Carried out in multidisciplinary collaboration across the Vall d'Hebron Barcelona Hospital Campus, results also evidence that this novel and less invasive approach can also provide precious insights into minimal residual disease, tumour evolution, and identify disease at relapse.

While the genomic characterisation of medulloblastoma promises a more precise molecular diagnosis, accessing tumour tissue -due to the very nature of its location- is complex and can suppose high-risk surgical procedures and stereotactic biopsies, neither of which can guarantee access to a truly representative part of the tumour.

The classification of this tumour type is also particularly challenging due to its ever changing intra-tumour heterogeneity which demands an in-depth and serial analysis of the evolving genomic landscapes in response to treatment or during disease recurrence.

Establishing the molecular make-up of medulloblastoma is particularly critical since this tumour type is the most common of all paediatric brain cancers.

"Results from this present study represent a potentially practice-changing approach in more precisely steering the surgical and clinical management of these young patients.

By evidencing the promise of cerebrospinal fluid as liquid biopsy for the personalised treatment of this extremely aggressive disease, our findings could ultimately spur the development of more effective and tailored therapeutic strategies.

As importantly, they could also reduce excessive treatment to prevent long-term secondary effects," observes corresponding author Joan Seoane, who also leads VHIO's Gene Expression and Cancer Group.

"Medulloblastoma is highly a complex, heterogenous tumour type that evolves over time.

Currently, acquiring further samples to monitor and track changes in the tumour to more precisely match the most effective therapy in real time represents a major challenge.

By liquid biopsy of cerebrospinal fluid, we aim to respond to the critical need of rendering the molecular characterisation and monitoring of this disease more precise," adds Laura Escudero, first author of the study and a Post-Doctoral Fellow of Joan's group at VHIO.

Hydrocephalus is an abnormal accumulation of cerebrospinal fluid and is very common in paediatric patients whose tumours are growing in the area of the posterior fossa, including medulloblastoma.

In these cases, cerebrospinal fluid drainage must be performed prior to surgery to reduce increased intracranial pressure (ICP).

Since the fluid is routinely collected for cytologic evaluation, this facilitates easy access to samples for research in the laboratory.

This latest research -supported through funding received from the Spanish Association against Cancer (AECC) and the Fero Foundation- demonstrates that the evaluation of cerebrospinal fluid can not only identify genomic alterations during tumour progression even before surgery, but also detect disease recurrence and track cancer progression to better inform treatment decision making in real time.

Data derived from the liquid biopsy is therefore fundamental in disease prognosis as well as gauging tumour aggressiveness.

This information is crucial for both the surgeon and the oncologist when balancing the risks and benefits of each intervention and therapeutic strategy.

The study investigators also show that CSF ctDNA facilitates the subgrouping and risk stratification of patients suffering from medulloblastoma, which provides valuable insights for the diagnosis and prognosis of disease towards more effectively matching therapies to the unique specificities of each individual patient.

Specifically, certain genetic mutations are critical in treatment selection, such as mutations in the PTCH1 gene which encodes a protein called patched-1. In this case, inhibitors of the Hedgehog signaling pathway could be a more effective treatment option.

"Our research represents an important forward step towards better characterising medulloblastoma, providing an earlier and more accurate molecular diagnosis, more closely monitoring our patients, and providing crucial data on minimal residual disease tumour evolution and disease at relapse.

Larger cohort studies are now warranted to bring cerebrospinal fluid as liquid biopsy closer to the clinic and deliver on the promise of precision medicine for the treatment of this disease," concludes Joan Seoane.